Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Scandinavian Journal of Gastroenterology Année : 2018

Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis

A. Dignass
  • Fonction : Auteur correspondant
A. Akbar
  • Fonction : Auteur
D.C. Baumgart
  • Fonction : Auteur
A. Gillessen
  • Fonction : Auteur
A. Hart
  • Fonction : Auteur
S. Hoque
  • Fonction : Auteur
R. Makins
  • Fonction : Auteur
P. Premchand
  • Fonction : Auteur
W. Ramlow
  • Fonction : Auteur
S. Schanz
  • Fonction : Auteur
C. von Tirpitz
  • Fonction : Auteur
B. Bonaz

Résumé

Objectives Current options for patients with steroid-dependent, chronic-active ulcerative colitis (UC) with insufficient response/intolerance to immunosuppressants (ISs) and/or biologics are limited. The aim of this study was to assess the long-term outcome of granulocyte/monocyte adsorptive (GMA) apheresis (Adacolumn®) in this population. Materials and methods Ninety five adults with steroid-dependent active UC and insufficient response/intolerance to IS and/or TNF inhibitors received 5–8 aphereses in a single induction series of ≤10 weeks. Endpoints included rates of remission (clinical activity index [CAI] ≤ 4) at weeks 24 and 48. Results Of 94 patients (ITT population), remission and response rates were 34.0% and 44.7% at week 24, and 33.0% and 39.4% at week 48. Among 30 patients with prior failure of IS and biologics, 33.3% and 20.0% were in remission at weeks 24 and 48. At both weeks, 19.2% of patients achieved steroid-free remission. Sustained remission or response occurred in 27.7% of patients at 48 weeks. The cumulative colectomy rate at week 96 was 23.4%. Safety was consistent with previous findings. Conclusions This study confirms findings of the 12-week interim analysis and demonstrates that GMA apheresis provides a safe and beneficial long-term outcome for patients with chronic active UC resistant/intolerant to IS and/or TNF inhibitors. © 2018 Informa UK Limited, trading as Taylor and Francis Group.
Fichier non déposé

Dates et versions

hal-01880990 , version 1 (25-09-2018)

Identifiants

Citer

A. Dignass, A. Akbar, D.C. Baumgart, G. Bommelaer, G. Bouguen, et al.. Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis. Scandinavian Journal of Gastroenterology, 2018, 53 (4), pp.442-448. ⟨10.1080/00365521.2018.1447598⟩. ⟨hal-01880990⟩
114 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More